32 filings
6-K
ABVX
Abivax S.A.
7 May 24
Availability of the preparatory documents
4:26pm
20-F
2023 FY
ABVX
Abivax S.A.
5 Apr 24
Annual report (foreign)
4:03pm
6-K
ABVX
Abivax S.A.
2 Apr 24
Abivax reports 2023 financial results and operational update
10:24am
6-K
ABVX
Abivax S.A.
2 Feb 24
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
6:05am
6-K
ABVX
Abivax S.A.
22 Jan 24
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
6:30am
424B4
g7apvdy
23 Oct 23
Prospectus supplement with pricing info
4:23pm
FWP
8xw62a9
20 Oct 23
Free writing prospectus
9:05am
EFFECT
r3x8a8d8rf7 tmn
20 Oct 23
Notice of effectiveness
12:15am
EFFECT
2kg8u5jq
20 Oct 23
Notice of effectiveness
12:15am
SEC STAFF LETTER
aq9ad 3l53mira6sr
20 Oct 23
SEC staff letter
12:00am
CERT
2ljmffwomn7 ap
19 Oct 23
Certification of approval for exchange listing
2:55pm
8-A12B
st87u iz99
18 Oct 23
Registration of securities on exchange
5:26pm
F-1/A
0a13sliyreodwtdhlbo
18 Oct 23
Registration statement (foreign) (amended)
5:22pm
CORRESP
ehj8392qwf481
18 Oct 23
Correspondence with SEC
12:00am
CORRESP
izyoft gtb
18 Oct 23
Correspondence with SEC
12:00am
CORRESP
qswg8z
18 Oct 23
Correspondence with SEC
12:00am
UPLOAD
hzmf3c5c
17 Oct 23
Letter from SEC
12:00am
F-1/A
xhr5nt1nh3ehokzjbu6
16 Oct 23
Registration statement (foreign) (amended)
11:23am
CORRESP
jwx4qvqbr b819j4sy
16 Oct 23
Correspondence with SEC
12:00am
UPLOAD
ohv17 70ou85piel1
5 Oct 23
Letter from SEC
12:00am